Evidence map›Paper›PMID 40938560›Full record

ArticleJapanese journal of radiology2026

Association between FDG accumulation in interstitial lesions and acute exacerbation risk in lung cancer: multicenter analysis.

Yuriko Ishida, Shiro Watanabe, Jun Sakakibara-Konishi, Yasuyuki Ikezawa, Hajime Kikuchi, Yasutaka Kawai, Hirokazu Kimura, Sho Nakakubo, Kenji Hirata, Kohsuke Kudo and 1 more

Abstract readMulticenter Study
In one paragraph

Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuriko IshidaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Shiro WatanabeDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita15, Nishi7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan. shirow@med.hokudai.ac.jp.ORCID http://orcid.org/0000-0002-7930-0975
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yasuyuki IkezawaDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Hajime KikuchiDepartment of Respiratory Medicine, Obihiro Kosei Hospital, Obihiro, Japan.
Yasutaka KawaiDepartment of Respiratory Medicine, Oji General Hospital, Tomakomai, Japan.
Hirokazu KimuraDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Sho NakakuboDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Kenji HirataDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita15, Nishi7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Kohsuke KudoDepartment of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Kita15, Nishi7, Kita-ku, Sapporo, Hokkaido, 060-8638, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInterstitial pneumonia (IP) is associated with poor prognosis in lung cancer and increases the risk of acute exacerbation (AE). Few studies analyzed the relationship between fluorodeoxyglucose (FDG) accumulation in IP with lung cancer complicated with IP and the incidence of AE. This study investigates the association between FDG accumulation in the interstitial lesions and the AE incidence in patients with lung cancer complicated with IP. MATERIALS AND

methodsThis multicenter, retrospective study included patients with lung cancer complicated with IP who received chemotherapy. All CTs at baseline and the onset of AE were centrally adjudicated. The SUVpeak and FDGscore for interstitial lesions were calculated from FDG positron emission tomography images before chemotherapy, and these values were corrected using reference uptake. To determine the association with AE risk, clinical characteristics and imaging findings were compared between patients who developed AE and those who did not. Subsequently, logistic regression analysis was performed to identify risk factors for the development of AE.

resultsOne hundred and thirteen patients who met the eligibility criteria were enrolled from three centers. However, 9 patients with a clinical diagnosis of collagen-related interstitial pneumonia were excluded due to predominant FDG accumulation in the interstitial lesions, and 104 patients were analyzed. Of those patients, 31.7% (33/104) developed all grade AE and 18.3% (19/104) developed grade 3 or higher. There were no significant differences in patient characteristics and imaging patterns between those with and without AE. SUVpeak in the ipsilateral and contralateral interstitial lesions to the tumor and the FDGscore did not differ between those with or without AE.

conclusionsNo association was observed between FDG accumulation in interstitial lesions and AE in patients with lung cancer complicated with IP. We may have to remain cautious about the risk of AE in lung cancer complicated with IP, even when FDG accumulation in interstitial lesions is high or low.

Indexed as

Fluorodeoxyglucose F18Lung Diseases, InterstitialLung NeoplasmsRadiopharmaceuticalsAgedAged, 80 and overDisease ProgressionFemaleHumansLungMaleMiddle AgedPositron Emission Tomography Computed TomographyRetrospective StudiesRisk FactorsTomography, X-Ray ComputedFluorodeoxyglucose F18RadiopharmaceuticalsAcute exacerbationFDGInterstitial pneumoniaLung cancerPETSUV

Identifiers

PMID40938560
PMCPMC12769495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.